Joint Research Program to Study Organ Toxicity
By Biotechdaily staff writers
Posted on 06 Feb 2003
A joint research program to develop and validate gene markers of drug-induced organ toxicity has been announced by Iconix Pharmaceuticals, Inc. (Mountain View, CA, USA) and Schering-Plough Research Institute (SPRI, Kenilworth, NJ, USA). Posted on 06 Feb 2003
The companies will study the genomic basis for certain forms of toxicity in the liver, kidney, and heart, with the aim of identifying and validating predictive toxicogenomic markers that may be useful in selecting candidate drug molecules earlier in the drug discovery cycle, thereby reducing animal safety testing. Iconix is pioneering the new field of chemogenomics, the integration of chemistry and genomics to profile drug candidates. SPRI is the pharmaceutical research and development arm of Schering-Plough Corp.
"Iconix brings to this collaboration a specialized set of chemogenomic and toxicogenomic assets and expertise that complements the drug discovery and toxicology capabilities of SPRI,” said Jim Neal, CEO of Iconix. "This synergy will help us to develop the use of genomics tools in drug optimization and toxicology and to validate this new area of science.”
Related Links:
Iconix
SPRI
Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
.jpg)
Gold Member
Rheumatoid Factors (RF) Test
Rheumatoid Factors (RF)
